These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24550375)

  • 1. Editorial commentary: Prophylactic echinocandin: is there a subgroup of intensive care unit patients who benefit?
    Muldoon EG; Denning DW
    Clin Infect Dis; 2014 May; 58(9):1227-9. PubMed ID: 24550375
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
    Glöckner A
    Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
    Ostrosky-Zeichner L; Shoham S; Vazquez J; Reboli A; Betts R; Barron MA; Schuster M; Judson MA; Revankar SG; Caeiro JP; Mangino JE; Mushatt D; Bedimo R; Freifeld A; Nguyen MH; Kauffman CA; Dismukes WE; Westfall AO; Deerman JB; Wood C; Sobel JD; Pappas PG
    Clin Infect Dis; 2014 May; 58(9):1219-26. PubMed ID: 24550378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of New Strategies for Echinocandins: Progress in Translational Research.
    Walsh TJ; Azie N; Andes DR
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
    Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.
    Vekeman F; Weiss L; Aram J; Ionescu-Ittu R; Moosavi S; Xiao Y; Cheng WY; Bhak RH; Tawadrous M; Capparella MR; Montravers P; Duh MS
    BMC Infect Dis; 2018 Aug; 18(1):438. PubMed ID: 30157797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.
    Hanson KE; Pfeiffer CD; Lease ED; Balch AH; Zaas AK; Perfect JR; Alexander BD
    PLoS One; 2012; 7(8):e42282. PubMed ID: 22879929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
    Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
    Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.